# Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study

> **NCT01156389** · PHASE1 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 34 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Ritonavir and Pyramax
- **DRUG:** Pyramax

## Key facts

- **NCT ID:** NCT01156389
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2010-08
- **Final completion:** 2010-09
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2023-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01156389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01156389, "Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01156389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*